Search research articles
Contact Us
Filters
Showing results (61-70 of 72) with videos related to
Page
of 8
Sort By:
The Journal of Experimental Medicine
|
March 23, 2000
Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity
F M Spada, E P Grant, P J Peters, et al.
European Journal of Organic Chemistry
|
December 31, 2020
Double Porphyrin Cage Compounds
Kathleen Stout, Theo P J Peters, Mathijs F J Mabesoone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2017
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
R J W van Kampen, B L T Ramaekers, D J A Lobbezoo, et al.
Breast Cancer Research and Treatment
|
October 10, 2013
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Dorien J A Lobbezoo, Roel J W van Kampen, Adri C Voogd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
British Journal of Cancer
|
April 17, 2015
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
JAMA Oncology
|
December 6, 2016
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial
Geert A Cirkel, Paul Hamberg, Stefan Sleijfer, et al.
Clinical Genitourinary Cancer
|
December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Saskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Clinical Genitourinary Cancer
|
December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands
Malou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Molecular Psychiatry
|
January 13, 2016
Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits
S V Trossbach, V Bader, L Hecher, et al.
Page
of 8
Search research articles
Search
Showing results (61-70 of 72) with videos related to
Sort By:
Page
of 8
The Journal of Experimental Medicine
|
March 23, 2000
Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity
F M Spada, E P Grant, P J Peters, et al.
European Journal of Organic Chemistry
|
December 31, 2020
Double Porphyrin Cage Compounds
Kathleen Stout, Theo P J Peters, Mathijs F J Mabesoone, et al.
European Journal of Cancer (Oxford, England : 1990)
|
March 2, 2017
Real-world and trial-based cost-effectiveness analysis of bevacizumab in HER2-negative metastatic breast cancer patients: a study of the Southeast Netherlands Breast Cancer Consortium
R J W van Kampen, B L T Ramaekers, D J A Lobbezoo, et al.
Breast Cancer Research and Treatment
|
October 10, 2013
Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome
Dorien J A Lobbezoo, Roel J W van Kampen, Adri C Voogd, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 19, 2015
In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium
D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
British Journal of Cancer
|
April 17, 2015
Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?
D J A Lobbezoo, R J W van Kampen, A C Voogd, et al.
JAMA Oncology
|
December 6, 2016
Alternating Treatment With Pazopanib and Everolimus vs Continuous Pazopanib to Delay Disease Progression in Patients With Metastatic Clear Cell Renal Cell Cancer: The ROPETAR Randomized Clinical Trial
Geert A Cirkel, Paul Hamberg, Stefan Sleijfer, et al.
Clinical Genitourinary Cancer
|
December 15, 2020
Real-world Data of Nivolumab for Patients With Advanced Renal Cell Carcinoma in the Netherlands: An Analysis of Toxicity, Efficacy, and Predictive Markers
Saskia Lisa Verhaart, Yasmin Abu-Ghanem, Sasja F Mulder, et al.
Clinical Genitourinary Cancer
|
December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the Netherlands
Malou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Molecular Psychiatry
|
January 13, 2016
Misassembly of full-length Disrupted-in-Schizophrenia 1 protein is linked to altered dopamine homeostasis and behavioral deficits
S V Trossbach, V Bader, L Hecher, et al.
Page
of 8